Read the interview with the Nepal Live Today – October 21, 2024.
On the sidelines of UNGA80, global health leaders explored ways to expand access to care and build resilient health systems, and the critical role partnerships play in ensuring sustainable impact. Read More
Building on two decades of progress, Max’s ambitious goal will expand its proven, patient-centered model that has already helped more than 100,000 people access treatment Commitment will enhance local health system capabilities to deliver innovative and generic medicines, diagnostics, and treatment in more than 80 low- and middle-income countries Alongside this commitment, Max and Novartis sign….
In 2017 The Max Foundation, through its subsidiary MaxAid, and Novartis have renewed their commitment to patients by launching CMLPath to Care™ a new collaboration aimed at providing humanitarian access to treatment for CML and other rare cancers for those patients for whom no other form of local treatment access exists today. CMLPath to Care consists of humanitarian product donations and funding support from Novartis to Max, and an innovative new distribution model developed and implemented by Max and its international distributor, under the Max Access Solution umbrella.
